A small Australian stem cell company is leading the world in the race to develop cells on a commercial scale and its chief Ross Macdonald says he is proud to “wave the flag” to show the country has a seat on the global stage.
Melbourne, Australia; 19 September 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 1 clinical
Melbourne, Australia; 5 September 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced the execution of a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. Pursuant to the term sheet, the parties will work together to seek to finalise a definitive agreement. If the parties enter into a definitive agreement, Cynata expects it to be finalised in the fourth quarter of 2016.
This is an exclusive interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016. He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.
Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its extensive internal databases of cellular products to develop an in-process assessment assay for Cynata’s unique Cymerus™ Cell Therapy (CT) products.
This follows an extensive period of feasibility assessment where Cynata evaluated the Sistemic technology portfolio and approach.
The development of CT products represents a major breakthrough in the potential to treat a wide range of diseases which are currently untreatable. Nevertheless, the sector has many challenges, not least in terms of standardisation and scale-up. The combination of Sistemic’s predictive miRNA technology, with the standardised and highly scalable technology from Cynata, presents a potential winning combination and paves the way for rapid industrialisation of a wide range of CT products which could revolutionise the way a wide range of diseases are treated.